Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment

World Journal of Gastroenterology

Volumn 18, Issue 27, 2012, Pages 3617-3622

  Shi, Hong ^a   Lu, Lu ^b   Zhang, Ning Ping ^a   Zhang, Shun Cai ^a   Shen, Xi Zhong ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Second People's Hospital   (China)

Author keywords

Covalently closed circular DNA; Hepatitis B virus; Interferon ; Lamivudine; Tumor necrosis factor

Indexed keywords

CIRCULAR DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; VIRUS LOAD;

EID: 84864317834     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i27.3617     Document Type: Article

References (35)

1. Huang LM, Lu CY, Chen DS. Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr Opin Immunol 2011; 23: 237-243.
2. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond) 2011; 61: 531-540.
3. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
4. Krastev ZA. The "return" of hepatitis B. World J Gastroenterol 2006; 12: 7081-7086.
5. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308.
6. Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol 2007; 81: 6164-6174.
7. Tsiang M, Gibbs CS. Analysis of hepatitis b virus dynamics and its impact on antiviral development. In: Hamatake RK, Lau JYN, editors. Hepatitis B and D protocols. Vol. 2. Immunology, model systems, and clinical studies. Totowa, NJ: Humana Press Inc., 2004: 361-377.
8. DS, Litwin S, Furman PA, Jilbert AR, Mason WS. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311-322.
9. Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Isom HC. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment. J Virol 2002; 76: 8148-8160.
10. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-S184.
11. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
12. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
13. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002; 2: 43-50.
14. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
15. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.
16. Shi H, Guan SH. Increased apoptosis in HepG2.2.15 cells with hepatitis B virus expression by synergistic induction of interferon-gamma and tumour necrosis factor-alpha;. Liver Int 2009; 29: 349-355.
17. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
18. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-129.
19. Leung N. Viral breakthrough during lamivudine therapy for chronic hepatitis B. Intervirology 2003; 46: 344-349.
20. Caruntu FA, Molagic V. CccDNA persistence during natural evolution of chronic VHB infection. Rom J Gastroenterol 2005; 14: 373-377.
21. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-1009.
22. Liu MC, Wang GQ, Piao WH, Xi HL, Lu HY, Wang Y, Wang QH. [Dynamic expression of hepatitis B virus covalently closed circular DNA in 2.2.15 cell]. Zhonghua Shiyan He Linchuang Bingduxue Zazhi 2005; 19: 391-394.
23. Liu MC, Yu M, Zhang NL, Gong WB, Wang Y, Piao WH, Wang QH, Wang GQ. Dynamic analysis of hepatitis B virus DNA and its antigens in 2.2.15 cells. J Viral Hepat 2004; 11: 124-129.
24. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
25. Schädler S, Hildt E. HBV life cycle: entry and morphogenesis. Viruses 2009; 1: 185-209.
26. Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004; 15: 299-305.
27. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592.
28. Puro R, Schneider RJ. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 2007; 81: 7351-7362.
29. Bertoletti A, D'Elios MM, Boni C, De Carli M, Zignego AL, Durazzo M, Missale G, Penna A, Fiaccadori F, Del Prete G, Ferrari C. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193-199.
30. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002; 76: 5646-5653.
31. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
32. Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8: 478-483.
33. Reifenberg K, Hildt E, Lecher B, Wiese E, Nusser P, Ott S, Yamamura K, Rutter G, Löhler J. IFNgamma expression inhibits LHBs storage disease and ground glass hepatocyte appearance, but exacerbates inflammation and apoptosis in HBV surface protein-accumulating transgenic livers. Liver Int 2006; 26: 986-993.
34. Herzer K, Sprinzl MF, Galle PR. Hepatitis viruses: live and let die. Liver Int 2007; 27: 293-301.
35. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997; 94: 8744-8749.